ES2200678B1 - Uso de la proteina mal como marcador tumoral. - Google Patents

Uso de la proteina mal como marcador tumoral.

Info

Publication number
ES2200678B1
ES2200678B1 ES200200615A ES200200615A ES2200678B1 ES 2200678 B1 ES2200678 B1 ES 2200678B1 ES 200200615 A ES200200615 A ES 200200615A ES 200200615 A ES200200615 A ES 200200615A ES 2200678 B1 ES2200678 B1 ES 2200678B1
Authority
ES
Spain
Prior art keywords
protein
marker
tumor marker
bad protein
bad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200200615A
Other languages
English (en)
Other versions
ES2200678A1 (es
Inventor
Miguel Angel Alonso Lebrero
Monica Marazuela Azpiroz
Agustin Luis Acevedo Barbera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOSPITAL de la PRINCESA
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
HOSPITAL de la PRINCESA
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200200615A priority Critical patent/ES2200678B1/es
Application filed by HOSPITAL de la PRINCESA, Consejo Superior de Investigaciones Cientificas CSIC filed Critical HOSPITAL de la PRINCESA
Priority to KR10-2004-7014489A priority patent/KR20040105771A/ko
Priority to PCT/ES2003/000119 priority patent/WO2003076948A1/es
Priority to MXPA04008962A priority patent/MXPA04008962A/es
Priority to AU2003216926A priority patent/AU2003216926A1/en
Priority to IL16357803A priority patent/IL163578A0/xx
Priority to JP2003575121A priority patent/JP2005520135A/ja
Priority to CA002476767A priority patent/CA2476767A1/en
Priority to EP03712142A priority patent/EP1930728A1/en
Priority to CNA038057565A priority patent/CN1643380A/zh
Priority to RU2004129773/15A priority patent/RU2004129773A/ru
Publication of ES2200678A1 publication Critical patent/ES2200678A1/es
Application granted granted Critical
Publication of ES2200678B1 publication Critical patent/ES2200678B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de la proteína MAL como marcador tumoral. La invención presente presenta la utilización de la proteína mal como un nuevo marcador y diana molecular en tumores epiteliales y otras patologías humanas. En concreto forma parte de la presente invención el uso de la detección de la proteína MAL como marcador con fines diagnósticos o pronósticos para tumores u otras patologías que afecten a células epiteliales, linfocitos T, mastocitos, células formadora de mielina o otros tipos celulares que normalmente expresen la proteína MAL.
ES200200615A 2002-03-14 2002-03-14 Uso de la proteina mal como marcador tumoral. Expired - Fee Related ES2200678B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES200200615A ES2200678B1 (es) 2002-03-14 2002-03-14 Uso de la proteina mal como marcador tumoral.
EP03712142A EP1930728A1 (en) 2002-03-14 2003-03-14 Use of the mal protein as a tumour marker
MXPA04008962A MXPA04008962A (es) 2002-03-14 2003-03-14 Uso de la proteina mal como marcador tumoral.
AU2003216926A AU2003216926A1 (en) 2002-03-14 2003-03-14 Use of the mal protein as a tumour marker
IL16357803A IL163578A0 (en) 2002-03-14 2003-03-14 Use of the mal protein as a tumour marker
JP2003575121A JP2005520135A (ja) 2002-03-14 2003-03-14 腫瘍マーカーとしてのｍａｌタンパク質の使用
KR10-2004-7014489A KR20040105771A (ko) 2002-03-14 2003-03-14 Ｍａｌ 단백질을 종양 표지자로 사용하는 방법
PCT/ES2003/000119 WO2003076948A1 (es) 2002-03-14 2003-03-14 Uso de la proteina mal como marcador tumoral
CNA038057565A CN1643380A (zh) 2002-03-14 2003-03-14 将mal蛋白作为肿瘤标记的应用
RU2004129773/15A RU2004129773A (ru) 2002-03-14 2003-03-14 Использование белка mal в качестве опухолевого маркера
CA002476767A CA2476767A1 (en) 2002-03-14 2003-03-14 Use of the mal protein as a tumour marker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200615A ES2200678B1 (es) 2002-03-14 2002-03-14 Uso de la proteina mal como marcador tumoral.

Publications (2)

Publication Number Publication Date
ES2200678A1 ES2200678A1 (es) 2004-03-01
ES2200678B1 true ES2200678B1 (es) 2005-06-01

Family

ID=27799028

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200200615A Expired - Fee Related ES2200678B1 (es) 2002-03-14 2002-03-14 Uso de la proteina mal como marcador tumoral.

Country Status (11)

Country Link
EP (1) EP1930728A1 (es)
JP (1) JP2005520135A (es)
KR (1) KR20040105771A (es)
CN (1) CN1643380A (es)
AU (1) AU2003216926A1 (es)
CA (1) CA2476767A1 (es)
ES (1) ES2200678B1 (es)
IL (1) IL163578A0 (es)
MX (1) MXPA04008962A (es)
RU (1) RU2004129773A (es)
WO (1) WO2003076948A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111295394B (zh) 2017-08-11 2024-06-11 豪夫迈·罗氏有限公司 抗cd8抗体及其用途
JP2022517917A (ja) * 2018-12-28 2022-03-11 ネオゼンティーシー コーポレーション Ｍａｌが発現された幹細胞様メモリーｔ細胞を有効成分として含む免疫増強又は抗癌活性促進用の組成物
EP3903805A4 (en) * 2018-12-28 2022-09-14 Neogentc Corp. (Convergence Innovation Building, Asan Institute for Life Sciences, Pungnap-dong) COMPOSITION OF OR ENHANCEMENT OF ANTI-CANCER OR IMMUNOSTIMULATING ACTIVITY COMPRISING A MAL-EXPRESSED STEM CELL-LIKE MEMORY T CELL AS AN ACTIVE INGREDIENT

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532383A (ja) * 2000-01-18 2003-11-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトポリヌクレオチド、ポリペプチド、および抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COPIE-BERGMAN, C. et al. "The MAL gene is expressed in primary mediastinal large B-cell lymphoma". BLOOD, 15 noviembre 1999, Vol. 94, nº 10, páginas 3567-3575, todo el documento. *
FRANK, M. et al. "Progressive segregation of unmyelinated axons in peripheral nerves, myelin alterations in the CNS, and cyst formation in the kidneys of myelin and lymphocyte protein-overexpressing mice". JOURNAL OF NEUROCHEMISTRY, 2000, Vol. 75, nº 5, páginas 1927-1939, todo el documento. *
MARTÍN-BELMONTE, F. et al. "Expression of the MAL gene in the thyroid: the MAL proteolipid, a component of glycolipid-enriched membranes, is apically distributed in thyroid follicles". ENDOCRINOLOGY, 1998, Vol. 139, nº 4, páginas 2077-2084, todo el documento. *
WAKEMAN, J.A. et al. "MAL mRNA is induced during the differentiation of human embryonal carcinoma cells into neurons and is also localised within specific regions of the human brain". DIFFERENTIATION, 1997, Vol. 62, páginas 97-105, resumen. *

Also Published As

Publication number Publication date
KR20040105771A (ko) 2004-12-16
IL163578A0 (en) 2005-12-18
RU2004129773A (ru) 2005-05-10
CA2476767A1 (en) 2003-09-18
AU2003216926A1 (en) 2003-09-22
JP2005520135A (ja) 2005-07-07
CN1643380A (zh) 2005-07-20
EP1930728A1 (en) 2008-06-11
ES2200678A1 (es) 2004-03-01
MXPA04008962A (es) 2005-06-03
WO2003076948A1 (es) 2003-09-18

Similar Documents

Publication Publication Date Title
GB2561940A (en) System and method for protein corona sensor array for early detection of diseases
CL2013000951A1 (es) Anticuerpo que presenta alta afinidad con proteinas tau solubles e insoluble y modula los niveles tau solubles e insolubles; peptido de union; composicion farmaceutica que comprende el peptido o proteina de union, un anticuerpo o polinucleotido; uso para tratar enfermedad neurodegenerativa.
Rossé et al. Control of MT1-MMP transport by atypical PKC during breast-cancer progression
MX2010009766A (es) Ensayo de proteasa.
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
PL2211180T3 (pl) Zastosowanie białka SATB2 jako markera do rozróżniania nowotworów jelita grubego od innych nowotworów
EA201070863A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
EP2560006A3 (en) Biomarkers for prostate cancer and methods using the same
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
WO2007149476A3 (en) Assays for non-apoptotic cell death and uses thereof
WO2007079284A3 (en) Lung cancer diagnostic assay
CY1119568T1 (el) Περιοχη δεσμευσης της βακτηριακης ατρ συνθασης
WO2008008708A3 (en) Lung cancer diagnostic assay
WO2009126969A3 (en) Biomarkers for endometrial disease
Tsaur et al. sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
WO2004062487A3 (en) Methods of detecting gene expression in normal and cancerous cells
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2005032347A3 (en) Determining the chemosensitivity of cells to cytotoxic agents
ES2200678B1 (es) Uso de la proteina mal como marcador tumoral.
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20040301

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2200678B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100312